# 5 Cardiovascular Benefits of GLP-1 Medications: What Research Shows **By TelosRX Clinical Team** · 2026-08-11 ![Man running through sunny forest path](https://images.unsplash.com/photo-1729280924877-4750c0dba51e?w=1400&q=80) **GLP-1 receptor agonists — including semaglutide and tirzepatide — do more than reduce body weight. Accumulated trial data show meaningful cardiovascular protection across five distinct mechanisms, independent of how much weight is lost.** When [TelosRX](https://telosrx.com) clinicians review cardiovascular risk with patients evaluating GLP-1 medications, the conversation often starts with weight. It rarely stays there. Large cardiovascular outcomes trials published over the past decade reveal that these medications work directly on the heart and vasculature in ways that extend well beyond caloric reduction. Below are five cardiovascular benefits supported by peer-reviewed outcomes data. ## 1\. Reduction in Major Adverse Cardiovascular Events (MACE) The most robust cardiovascular evidence for GLP-1 receptor agonists comes from dedicated cardiovascular outcomes trials (CVOTs), where the primary endpoint is a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke — collectively called MACE. Trial Agent MACE Reduction Population Follow-up SELECT (2023) Semaglutide 2.4 mg 20% relative risk reduction Overweight/obese, established CVD, no T2D ~3.3 years SUSTAIN-6 (2016) Semaglutide 0.5/1 mg 26% relative risk reduction T2D, high CV risk 2 years SURPASS-CVOT (2024) Tirzepatide ~14% (preliminary) T2D, established CVD or high risk Ongoing/interim Nature Medicine 2025 Multiple GLP-1 RAs Consistent benefit across agents Meta-analysis across CVOTs Pooled The SELECT trial's significance: it was the first large CVOT to demonstrate MACE reduction in people without type 2 diabetes, establishing that cardiovascular benefit is not simply a downstream effect of glucose control. Source: [NEJM, SELECT Trial, 2023](https://www.nejm.org/doi/full/10.1056/NEJMoa2307563) ## 2\. Blood Pressure Reduction Across most GLP-1 receptor agonist trials, systolic blood pressure decreases by 2–5 mmHg from baseline. While modest in isolation, reductions at this magnitude correspond to meaningful reductions in stroke and cardiac event risk at population scale. Two mechanisms are thought to contribute: - **Natriuresis:** GLP-1 receptors are expressed in the kidney. Activation increases sodium excretion, reducing plasma volume and blood pressure — a mechanism similar to but distinct from SGLT2 inhibitors. - **Nitric oxide upregulation:** GLP-1 receptor activation in endothelial cells stimulates nitric oxide synthase, promoting vasodilation. This effect has been documented in animal models and human endothelial cell cultures. Blood pressure reduction with GLP-1 receptor agonists appears partially independent of weight loss, persisting in statistical analyses that control for BMI change. ## 3\. Improvement in Heart Failure with Preserved Ejection Fraction (HFpEF) HFpEF — a form of heart failure where the heart contracts normally but the ventricles are stiff — has historically been difficult to address pharmacologically. Two recent trials changed that picture. **STEP-HFpEF (2023):** In 529 patients with obesity-related HFpEF (no diabetes), weekly semaglutide 2.4 mg versus placebo produced significant improvements in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores (+7.8 points vs. placebo), 6-minute walk distance, and body weight. **SUMMIT (2024):** Tirzepatide in HFpEF patients with obesity demonstrated comparable improvements — better exercise capacity, symptom scores, and weight reduction versus placebo. Both trials showed meaningful functional improvement. Neither was powered to detect mortality differences. Source: [STEP-HFpEF, NEJM 2023](https://www.nejm.org/doi/full/10.1056/NEJMoa2306963) ## 4\. Favorable Lipid Profile Changes GLP-1 receptor agonists consistently produce improvements across lipid panels: - **LDL cholesterol:** Average reductions of 3–5% in larger trials — modest but additive to overall atherogenic risk reduction. - **Triglycerides:** More substantial reductions, often 15–25%. Elevated triglycerides are an independent cardiovascular risk factor, particularly in metabolic syndrome and insulin resistance. - **HDL cholesterol:** Modest increases consistent with improved insulin sensitivity and weight reduction. The triglyceride effect is particularly notable in patients with non-alcoholic fatty liver disease or metabolic syndrome — populations where GLP-1 receptor agonists show the largest overall metabolic benefit. ## 5\. Anti-Inflammatory and Endothelial Effects Chronic low-grade inflammation drives atherosclerosis progression. GLP-1 receptor agonists appear to reduce several inflammatory markers relevant to cardiovascular risk. A [Journal of Clinical Investigation (2020)](https://www.jci.org) study demonstrated that semaglutide reduced circulating TNF-α and IL-6 — pro-inflammatory cytokines closely linked to endothelial dysfunction and plaque instability. High-sensitivity CRP (hs-CRP) also falls with GLP-1 receptor agonist use. Additional endothelial effects documented in the literature: - Reduced expression of adhesion molecules (ICAM-1, VCAM-1) that facilitate leukocyte recruitment to vessel walls - Improved endothelial-dependent vasodilation in brachial artery flow-mediated dilation studies - Reduced oxidative stress markers in vascular tissue These effects appear to occur through direct GLP-1 receptor activation on immune cells and vascular endothelium — additive to the metabolic benefits of weight loss. ## What This Means for Clinical Evaluation If you are evaluating GLP-1 medications through [TelosRX’s asynchronous care program](https://www.telosrx.com/collections/glp-1), your evaluation includes a clinical review of cardiovascular history and risk factors. Compounded GLP-1 medications available through TelosRX are not FDA-approved and are prepared under federal compounding regulations. Use is subject to medical approval by a licensed provider; approval is not guaranteed. The cardiovascular data summarized here comes from trials of branded GLP-1 formulations. Outcomes data for compounded formulations specifically has not been separately established. ## Frequently Asked Questions ### Do GLP-1 medications protect the heart in people without diabetes? Yes. The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4 mg in people with obesity and established cardiovascular disease but no type 2 diabetes — the first large-scale CVOT to show this in a non-diabetic population. ### How long does it take for cardiovascular benefits to appear? In the SELECT trial, separation in MACE curves appeared within the first few months and widened progressively over the approximately 3.3-year follow-up. Blood pressure and inflammatory marker changes may appear sooner. ### Are the cardiovascular benefits just from weight loss? Not entirely. Statistical analyses controlling for weight loss show that a meaningful portion of the MACE benefit, blood pressure reduction, and anti-inflammatory effects persist independently of how much weight is lost. ### Does tirzepatide have the same cardiovascular benefits as semaglutide? Tirzepatide (a dual GLP-1/GIP receptor agonist) is under evaluation in SURPASS-CVOT. Preliminary data suggest cardiovascular benefit, and the SUMMIT trial showed HFpEF functional improvements. Full CVOT results are pending. ### Can someone with a heart disease history use GLP-1 medications through TelosRX? Cardiovascular history is reviewed during the clinical intake process. Use is subject to evaluation and approval by a licensed provider. TelosRX operates as an asynchronous telehealth service and is not a substitute for ongoing management of established cardiovascular disease with a cardiologist. Start your private evaluation at [TelosRX](https://telosrx.com). _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ **Tags:** cardiovascular, GLP-1, heart health, listicle, MACE, semaglutide, tirzepatide --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/glp1-cardiovascular-benefits-research)